Risk of progression of Barrett's esophagus in patients with cirrhosis

被引:3
|
作者
Apfel, Tehilla [1 ]
Lopez, Rocio [1 ]
Sanaka, Madhusudhan R. [1 ]
Thota, Prashanthi N. [1 ]
机构
[1] Cleveland Clin Fdn, Dept Gen Internal Med, Cleveland, OH 44195 USA
关键词
Liver cirrhosis; Barrett's esophagus; Dysplasia; Esophageal neoplasm; Progression; NONALCOHOLIC FATTY LIVER; HIGH-GRADE DYSPLASIA; GASTROESOPHAGEAL-REFLUX; METABOLIC SYNDROME; ADENOCARCINOMA; VARICES; METAANALYSIS; ADIPOKINES; DISEASE;
D O I
10.3748/wjg.v23.i18.3287
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM To study Barrett's esophagus (BE) in cirrhosis and assess progression to esophageal adenocarcinoma (EAC) compared to non-cirrhotic BE controls. METHODS Cirrhotic patients who were found to have endoscopic evidence of BE confirmed by the presence of intestinal metaplasia on histology from 1/1/2000 to 12/1/2015 at Cleveland Clinic were included. Cirrhotic patients were matched 1: 4 to BE controls without cirrhosis. Age, gender, race, BE length, hiatal hernia size, Child-Pugh (CP) class and histological findings were recorded. Cases and controls without high-grade dysplasia (HGD)/EAC and who had follow-up endoscopies were studied for incidence of dysplasia/EAC and to assess progression rates. Univariable conditional logistic regression was done to assess differences in baseline characteristics between the two groups. RESULTS A total of 57 patients with cirrhosis and BE were matched with 228 controls (BE without cirrhosis). The prevalence of dysplasia in cirrhosis and controls were similar with 8.8% vs 12% with low grade dysplasia (LGD) and 12.3 % vs 19.7% with HGD or EAC (P = 0.1). In the incidence cohort of 44 patients with median follow-up time of 2.7 years [interquartile range 1.0, 4.8], there were 7 cases of LGD, 2 cases of HGD, and 2 cases of EAC. There were no differences in incidence rates of HGD/ EAC in nondysplastic BE between cirrhotic cases and noncirrhotic controls (1.4 vs 1.1 per 100 person-years, P = 0.8). In LGD, cirrhotic patients were found to have higher rates of progression to HGD/EAC compared to control group though this did not reach statistical significance (13.7 vs 8.1 per 100 person-years, P = 0.51). A significant association was found between a higher CP class and neoplastic progression of BE in cirrhotic patients (HR = 7.9, 95% CI: 2.0-30.9, P = 0.003). CONCLUSION Cirrhotics with worsening liver function are at increased risk of progression of BE. More frequent endoscopic surveillance might be warranted in such patients.
引用
收藏
页码:3287 / 3294
页数:8
相关论文
共 50 条
  • [31] Barrett’s Esophagus: Model of Neoplastic Progression
    Stig Ramel
    World Journal of Surgery, 2003, 27 : 1009 - 1013
  • [32] Barrett's esophagus: progression to adenocarcinoma and markers
    Fang, Dianchun
    Das, Kiron M.
    Cao, Weibiao
    Malhotra, Usha
    Triadafilopoulos, George
    Najarian, Robert M.
    Hardie, Laura J.
    Lightdale, Charles J.
    Beales, Ian L. P.
    Felix, Valter Nilton
    Schneider, Paul M.
    Bellizzi, Andrew M.
    BARRETT'S ESOPHAGUS: THE 10TH OESO WORLD CONGRESS PROCEEDINGS, 2011, 1232 : 210 - 229
  • [33] Progression of Barrett's esophagus in the German registry
    Fuchs, KH
    Fein, M
    Maroske, J
    GASTROENTEROLOGY, 2004, 126 (04) : A795 - A795
  • [34] Barrett's esophagus: Model of neoplastic progression
    Ramel, S
    WORLD JOURNAL OF SURGERY, 2003, 27 (09) : 1009 - 1013
  • [35] Length of Barrett's Esophagus Predicts Progression
    Ngo, Catherine
    Mann, Surinder
    Leung, Joseph
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S398 - S398
  • [36] Prevalence, Natural History, and Management of Suspected Barrett's Esophagus in Patients with Cirrhosis
    Hussan, Hisham
    Bhatia, Ruchi
    Hilton, Robert
    Ringwala, Jalpan
    Hachem, Christine
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 : S34 - S34
  • [37] Risk Factors for Predicting Neoplastic Progression in Patients With Barrett's Esophagus and Low-Grade Dysplasia
    Zavos, Christos
    Verbeek, Romy E.
    Leenders, Max
    Moons, Leon M.
    Vleggaar, Frank P.
    Siersema, Peter D.
    GASTROENTEROLOGY, 2013, 144 (05) : S675 - S676
  • [38] Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia
    Parasa, Sravanthi
    Vennalaganti, Sreekar
    Gaddam, Srinivas
    Vennalaganti, Prashanth
    Young, Patrick
    Gupta, Neil
    Thota, Prashanthi
    Cash, Brooks
    Mathur, Sharad
    Sampliner, Richard
    Moawad, Fouad
    Lieberman, David
    Bansal, Ajay
    Kennedy, Kevin F.
    Vargo, John
    Falk, Gary
    Spaander, Manon
    Bruno, Marco
    Sharma, Prateek
    GASTROENTEROLOGY, 2018, 154 (05) : 1282 - +
  • [39] Characteristics of patients with columnar-lined Barrett's esophagus and risk factors for progression to esophageal adenocarcinoma
    Bani-Hani, Kamal E.
    Bani-Hani, Bayan K.
    Martin, Iain G.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2005, 11 (43) : 6807 - 6814
  • [40] Characteristics of patients with columnar-lined Barrett's esophagus and risk factors for progression to esophageal adenocarcinoma
    Kamal E Bani-Hani
    Bayan K Bani-Hani
    Iain G Martin
    World Journal of Gastroenterology, 2005, (43) : 6807 - 6814